» Articles » PMID: 15925080

Sexual Dysfunction and Lower Urinary Tract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia (BPH)

Overview
Journal Eur Urol
Specialty Urology
Date 2005 Jun 1
PMID 15925080
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Sexuality is an essential aspect of a couple's relationship and has a significant impact on life satisfaction. Benign prostatic hyperplasia (BPH) is a condition that commonly affects older men and is often associated with lower urinary tract symptoms (LUTS) and sexual dysfunction. Men with moderate-to-severe LUTS are at increased risk for sexual dysfunction, including moderate-to-severe erectile dysfunction (ED), ejaculatory dysfunction (EjD), and hypoactive desire (HD). The results of several recent large-scale studies have shown a consistent and strong relationship between LUTS and both ED and EjD. It appears that the pathophysiological mechanisms of LUTS and the related prostatic enlargement of BPH as well as certain treatments for this condition may have an impact on both the erection and ejaculation components of the sexual response. Validated questionnaires that assess sexual function provide clinicians with valuable information to help guide treatment selection decisions. Effective medical therapies for LUTS associated with BPH include alpha(1)-adrenergic receptor antagonists (i.e., alfuzosin, doxazosin, tamsulosin, and terazosin) and 5alpha-reductase inhibitors (i.e., finasteride and dutasteride). The side effects of these medications, including sexual dysfunction, are important distinguishing features. The successful management of patients with LUTS associated with BPH should include assessments of sexual function and monitoring of medication-related sexual side effects. For men with LUTS and sexual dysfunction, an appropriate integrated management approach, based on each patient's symptoms and outcome objectives, is warranted.

Citing Articles

Comparative efficacy and safety of greenlight laser vaporization, anatomical vaporization, and enucleation for benign prostatic hyperplasia: a systematic review and meta-analysis.

Wang M, Chen S, Xi Y, Huang N, Zhang L, Liu J Lasers Med Sci. 2025; 40(1):139.

PMID: 40085272 DOI: 10.1007/s10103-025-04389-9.


Comparative efficacy and safety of 180 W XPS . 120 W HPS GreenLight laser therapy for benign prostatic hyperplasia: a systematic review and meta-analysis.

Wang M, Xi Y, Qiu Z, Huang N, Zhang L, Liu J PeerJ. 2024; 12:e18615.

PMID: 39619178 PMC: 11608016. DOI: 10.7717/peerj.18615.


The Role of 5-Phosphodiesterase Inhibitors (PDE-5I) in Current Benign Prostatic Hyperplasia Treatment: A Narrative Review.

Stamatiou K, Perletti G, Magri V, Trinchieri A Medicina (Kaunas). 2024; 60(11).

PMID: 39596921 PMC: 11595904. DOI: 10.3390/medicina60111736.


Lower urinary tract symptoms among male patients on hemodialysis: Prospective and multi-central cross-sectional study.

Abushamma F, Zidan E, Douglass Z, Jaber A, Nazzal Z, Hamdan Z SAGE Open Med. 2024; 12:20503121241263302.

PMID: 39092156 PMC: 11292685. DOI: 10.1177/20503121241263302.


Evaluating the Impact of Benign Prostatic Hyperplasia Surgical Treatments on Sexual Health.

Kaltsas A, Kratiras Z, Zachariou A, Dimitriadis F, Sofikitis N, Chrisofos M Biomedicines. 2024; 12(1).

PMID: 38255215 PMC: 10813562. DOI: 10.3390/biomedicines12010110.